Clinical Trials Logo

HER2-positive Gastric Cancer clinical trials

View clinical trials related to HER2-positive Gastric Cancer.

Filter by:

NCT ID: NCT03330561 Completed - Clinical trials for HER2-positive Breast Cancer

PRS-343 in HER2-Positive Solid Tumors

Start date: September 13, 2017
Phase: Phase 1
Study type: Interventional

A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.

NCT ID: NCT03319459 Completed - Colorectal Cancer Clinical Trials

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

Start date: January 18, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: - Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. - Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. - Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.

NCT ID: NCT02378389 Recruiting - Clinical trials for HER2 Positive Gastric Cancer

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

Start date: September 2014
Phase: Phase 1
Study type: Interventional

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in combination with Docetaxel in patients with HER2 positive advanced gastric cancer.